Goldman Sachs
SAGE

Goldman Sachs’s Sage Therapeutics SAGE Stock Holding History

Goldman Sachs’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-20,000
Closed -$1.5M – 6476
2021
Q1 		$1.5M Buy
+20,000
New +$1.64M ﹤0.01% 4273
2020
Q2 		– Sell
-77,300
Closed -$2.22M – 5450
2020
Q1 		$2.22M Buy
+77,300
New +$4.48M ﹤0.01% 3225
2018
Q1 		– Sell
-106,900
Closed -$17.6M – 6333
2017
Q4 		$17.6M Sell
106,900
-70,000
-40% -$6.79M ﹤0.01% 2032
2017
Q3 		$11M Sell
176,900
-442,500
-71% -$34.8M ﹤0.01% 2485
2017
Q2 		$49.3M Buy
+619,400
New +$44.8M 0.01% 1248
2016
Q2 		– Sell
-50,000
Closed -$1.6M – 7219
2016
Q1 		$1.6M Sell
50,000
-50,000
-50% -$1.76M ﹤0.01% 3681
2015
Q4 		$5.83M Buy
100,000
+75,000
+300% +$3.72M ﹤0.01% 2688
2015
Q3 		$1.06M Buy
+25,000
New +$1.54M ﹤0.01% 4419

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Goldman Sachs's SAGE Position: Q3 2025 in Review

Goldman Sachs sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 519,107 shares — an estimated $4.73M sold.

Goldman Sachs first reported a position in SAGE in Q3 2014 and held it in 44 quarters. The position peaked at $66.2M in Q2 2018. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Goldman Sachs reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Goldman Sachs sold 519,107 Sage Therapeutics shares in Q3 2025, an estimated $4.73M.
  • Goldman Sachs first reported a position in Sage Therapeutics in Q3 2014 and held it in 44 quarters.
  • Goldman Sachs's Sage Therapeutics position peaked at $66.2M in Q2 2018.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Goldman Sachs's 13F filing for Q3 2025, filed 14 Nov 2025.